These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23551924)

  • 1. Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis.
    Kishi T; Meltzer HY; Iwata N
    Int J Neuropsychopharmacol; 2013 Jul; 16(6):1259-66. PubMed ID: 23551924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive azapirone for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.
    Zheng W; Li XH; Cai DB; Yang XH; Ungvari GS; Ng CH; Ning YP; Xiang YT
    Eur Neuropsychopharmacol; 2018 Jan; 28(1):149-158. PubMed ID: 29174529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azapirone 5-HT1A receptor partial agonist treatment for major depressive disorder: systematic review and meta-analysis.
    Kishi T; Meltzer HY; Matsuda Y; Iwata N
    Psychol Med; 2014 Aug; 44(11):2255-69. PubMed ID: 24262766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 5-HT1A Receptor Partial Agonists of the Azapirone Class as an Add-On Therapy on Psychopathology and Cognition in Schizophrenia: A Systematic Review and Meta-Analysis.
    Yamada R; Wada A; Stickley A; Yokoi Y; Sumiyoshi T
    Int J Neuropsychopharmacol; 2023 Apr; 26(4):249-258. PubMed ID: 36721972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
    Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY
    Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation therapy with serotonin
    Yamada R; Wada A; Stickley A; Yokoi Y; Sumiyoshi T
    Schizophr Res Cogn; 2023 Dec; 34():100290. PubMed ID: 37732133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia.
    Ghaleiha A; Noorbala AA; Farnaghi F; Hajiazim M; Akhondzadeh S
    J Clin Psychopharmacol; 2010 Dec; 30(6):678-82. PubMed ID: 21105281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials.
    Kishi T; Iwata N
    J Psychiatr Res; 2013 Sep; 47(9):1143-9. PubMed ID: 23692933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials.
    Correll CU; Maayan L; Kane J; Hert MD; Cohen D
    J Clin Psychiatry; 2016 Jun; 77(6):e746-56. PubMed ID: 27337425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: a meta-analysis of double-blind randomized placebo-controlled trials.
    Kishi T; Mukai T; Matsuda Y; Moriwaki M; Iwata N
    J Psychiatr Res; 2013 Nov; 47(11):1557-63. PubMed ID: 23899496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Oya K; Kishi T; Iwata N
    Hum Psychopharmacol; 2014 Sep; 29(5):483-91. PubMed ID: 25087702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Zheng W; Li XH; Yang XH; Cai DB; Ungvari GS; Ng CH; Wang SB; Wang YY; Ning YP; Xiang YT
    Psychol Med; 2018 Jan; 48(1):72-81. PubMed ID: 28528597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials.
    Srisurapanont M; Suttajit S; Maneeton N; Maneeton B
    J Psychiatr Res; 2015 Mar; 62():38-47. PubMed ID: 25619176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia.
    Kishi T; Iwata N
    Int J Neuropsychopharmacol; 2014 Feb; 17(2):343-54. PubMed ID: 23823741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.
    Galling B; Roldán A; Rietschel L; Hagi K; Walyzada F; Zheng W; Cao XL; Xiang YT; Kane JM; Correll CU
    Expert Opin Drug Saf; 2016 May; 15(5):591-612. PubMed ID: 26967126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials.
    Zheng W; Xiang YT; Xiang YQ; Li XB; Ungvari GS; Chiu HF; Correll CU
    Acta Psychiatr Scand; 2016 Nov; 134(5):385-398. PubMed ID: 27585549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials.
    Oya K; Matsuda Y; Matsunaga S; Kishi T; Iwata N
    Eur Arch Psychiatry Clin Neurosci; 2016 Aug; 266(5):439-50. PubMed ID: 26303414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive ondansetron for schizophrenia: A systematic review and meta-analysis of randomized controlled trials.
    Zheng W; Cai DB; Zhang QE; He J; Zhong LY; Sim K; Ungvari GS; Ning YP; Xiang YT
    J Psychiatr Res; 2019 Jun; 113():27-33. PubMed ID: 30878789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia.
    Galling B; Vernon JA; Pagsberg AK; Wadhwa A; Grudnikoff E; Seidman AJ; Tsoy-Podosenin M; Poyurovsky M; Kane JM; Correll CU
    Acta Psychiatr Scand; 2018 Mar; 137(3):187-205. PubMed ID: 29431197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.